|
Amgen, AMGN
2008-03-09 02:57:00 9.3-2008 BloodMoney in the WallStreet. Amgen bearish wedge (nice size youīre agree?) I left this one to be very clear off waves, I think itīs exellent example how stockpatterns behave. Size of the bigger bearish wedge is exact 44 $ (high-low).Stock Charts Courtesy of www.WallStreetTape.com
By: Just Charts
Investing in Biotechnology: One Market Is Always a Bull Market
2008-02-21 20:37:00 It?s getting tougher and tougher to find safety. The tech sector is getting hit. Formerly high flying overseas are giving back some of their handsome gains. Even with oil prices hitting $100 a barrel again yesterday, the entire oil sector is off about 10% for the year. The bears have had their way. And, frankly, there ...
By: Jutia Group
Takeda Pharmaceutical Co. aquires the local unit of Amgen Inc.
2008-02-06 00:00:00 Takeda Pharmaceutical Co., Japan’s largest drug maker, agreed to buy the local unit of Amgen Inc. for as much as $902 million, gaining about a dozen experimental medicines for diseases including cancer and arthritis. Takeda will pay $200 million in cash initially and $702 million in additional payments. Thousand Oaks, California-based Amgen will also receive ...
By: Blog economie
Value investors vote for Amgen (AMGN)
2007-11-02 06:00:00 “While the stock has rebounded a bit from its August lows, we view this as a great opportunity to buy Amgen (quote.htm?sym=amgn) (NASDAQ: AMGN (quote.htm?sym=amgn)), one of the premier names in a key industry,” says George Putnam (ccount/click.php?id=1465). In his industry-leading The Turnaround Letter (ccount/click.php?id=1465), he explains, “An interesting list of value investors, including David Dreman and Bill Miller, have accumulated the stock. We recommend joining them.” Here is his review.
Amgen Plans to Cut Work Force
2007-09-19 08:47:00 August 15, 2007 4:06 p.m. Amgen Inc. announced plans to cut its work force by 12% to 14% amid a slump in its top-selling anemia drug Aranesp. The company also reduced its earnings outlook for the year. More details are expected shortly. Second-quarter sales of Aranesp, Amgen's biggest product, slumped 19% to $578 million from $713 million a year earlier. Aranesp is prescribed to boost flagging red-blood-cell counts in patients suffering anemia due to kidney disease and cancer chemotherapy. Studies of risks of heart disease and cancer pr
Amgen (AMGN)
2007-08-13 16:54:00 13.8-2007 Amgen Elliott Wave Chart Update. As mentioned before didnīt have a clue what Amgen is doing, but might have now. Take a deep breath and look the older chart also whatīs located in the left side and which price target it pinpoints. This company is also most heavy component in Biotechnology Index (besides itīs also one QQQQ/NDX component).
By: Just Charts
Amgen: A who's who of value investors
2007-08-08 18:33:00 “The list of prominent investors who have a stake in Amgen (NASDAQ: AMGN) reads like a ‘Who's Who’ of value investing,” says Nathan Slaughter.In his Half-Priced Stocks, he says, “In fact, Eddie Lampert, George Soros, David Dreman, Richard Pzena, and Bill Miller all own Amgen, several of those have added to their position at prices above where the stock is trading today.” Here is his review of the biotech firm. “The California-based firm has leveraged its expertise in cellular and molecular biology to develop treatments for a wide range of ailments, including cancer, kidney disease, inflammation, and neurological and metabolic disorders. “Thanks in part to a handful of blockbuster drugs, Amgen's sales have jumped 29% annually over the past five years, climbing from $4 billion in 2001 to $14.2 billion last year. Meanwhile, operating cash flows have nearly quadrupled to reach $5.4 billion. “Yet despite that impressive perfo...
Amgen Dependance on Aranesp Off-Label Use Greatly Exaggerated
2007-05-14 16:32:00 I touched on the issues Amgen (AMGN) is having with Aranesp a couple months back, but I decided to take a closer look at the numbers after the latest news that an FDA panel recommended further studies and label changes for the company's anemia drug franchise. Such recommendations should not have been surprising given that a label change was already in the works (albeit less severe) and companies do follow-up studies on existing drugs all the time to measure long-term effects.The main concern with Aranesp is that the drug is approved for patients with hemoglobin levels below 12. However, there is off-label usage going on at higher levels, and the FDA is concerned that such usage may increase cancer patients' risk of developing other health problems. Amgen stock has been crushed on these concerns, slumping from 77 to 56 per share in the last year. Is the company going to lose as much business as Wall Street seems to be pricing in? I decided to take a look.The media and Wall Stre...
Does Amgen deserve to be at a 2 year low?
2007-04-06 06:31:00 Amgen (AMGN) is the world's leading biotech company. It is currently trading at $55.73 which is close to it's 2 year low. Does it really deserve the house of pain?.....
Patient Investors: Take a Look at Amgen
2007-03-26 14:49:00 As a value investor, it is often easier to find undiscovered or unloved stocks in the small and mid cap universe. After all, bigger companies are well known, followed by more analysts, and are very popular with retail investors. Those... |
|
 |
|
 |
